Current:Home > MyAutoimmune disease patients hit hurdles in diagnosis, costs and care -BeyondProfit Compass
Autoimmune disease patients hit hurdles in diagnosis, costs and care
View
Date:2025-04-15 02:02:25
After years of debilitating bouts of fatigue, Beth VanOrden finally thought she had an answer to her problems in 2016 when she was diagnosed with Hashimoto's disease, an autoimmune disorder.
For her and millions of other Americans, that's the most common cause of hypothyroidism, a condition in which the thyroid, a butterfly-shaped gland in the neck, doesn't produce enough of the hormones needed for the body to regulate metabolism.
There's no cure for Hashimoto's or hypothyroidism. But VanOrden, who lives in Athens, Texas, started taking levothyroxine, a much-prescribed synthetic thyroid hormone used to treat common symptoms, like fatigue, weight gain, hair loss, and sensitivity to cold.
Most patients do well on levothyroxine and their symptoms resolve. Yet for others, like VanOrden, the drug is not as effective.
For her, that meant floating from doctor to doctor, test to test, and treatment to treatment, spending about $5,000 a year.
"I look and act like a pretty energetic person," says VanOrden, 38, explaining that her symptoms are not visible. "But there is a hole in my gas tank," she says. And "stress makes the hole bigger."
Autoimmune diseases occur when the immune system mistakenly attacks and damages healthy cells and tissues. Other common examples include rheumatoid arthritis, lupus, celiac disease, and inflammatory bowel disease. There are more than 80 such diseases, affecting up to an estimated 50 million Americans, disproportionately women. Overall, the cost of treating autoimmune diseases is estimated at more than $100 billion annually in the U.S.
Despite their frequency, finding help for many autoimmune diseases can prove frustrating and expensive. Getting diagnosed can be a major hurdle because the range of symptoms looks a lot like those of other medical conditions, and there are often no definitive identifying tests, says Dr. Sam Lim, clinical director of the Division of Rheumatology at Emory University School of Medicine in Atlanta. In addition, some patients feel they have to fight to be believed, even by a clinician. And after a diagnosis, many autoimmune patients rack up big bills as they explore treatment options.
"They're often upset. Patients feel dismissed," Dr. Elizabeth McAninch, an endocrinologist and thyroid expert at Stanford University, says of some patients who come to her for help.
Insufficient medical education and lack of investment in new research are two factors that hinder overall understanding of hypothyroidism, according to Antonio Bianco, a University of Chicago endocrinologist and leading expert on the condition.
Some patients become angry when their symptoms don't respond to standard treatments, either levothyroxine or that drug in combination with another hormone, says Douglas Ross, an endocrinologist at Massachusetts General Hospital in Boston. "We will have to remain open to the possibility that we're missing something here," he says.
Jennifer Ryan, 42, says she has spent "thousands of dollars out-of-pocket" looking for answers. Doctors did not recommend thyroid hormone medication for the Huntsville, Alabama, resident — diagnosed with Hashimoto's after years of fatigue and weight gain — because her levels appeared normal. She recently switched doctors and hopes for the best.
"You don't walk around hurting all day long and have nothing wrong," Ryan says.
And health insurers typically deny coverage of novel hypothyroidism treatments, says Brittany Henderson, an endocrinologist and founder of the Charleston Thyroid Center in South Carolina, which sees patients from all 50 states. "Insurance companies want you to use the generics even though many patients don't do well with these treatments," she says.
Meanwhile, the extent of Americans' thyroid problems can be seen in drug sales. Levothyroxine is among the five most prescribed medications in the U.S. every year. Yet research points to some overprescribing of the drug for those with mild hypothyroidism.
A recent study, paid for by AbbVie — maker of Synthroid, a brand-name version of levothyroxine — said a medical and pharmacy claims database showed that the prevalence of hypothyroidism, including milder forms, rose from 9.5% of Americans in 2012 to 11.7% in 2019.
The number of people diagnosed will rise as the population ages, says McAninch. Endocrine disruptors — natural or synthetic chemicals that can affect hormones — could account for some of that increase, she says.
In their search for answers, patients sometimes connect on social media, where they ask questions and describe their thyroid hormone levels, drug regimens, and symptoms. Some online platforms offer information that's dubious at best, but overall, social media outlets have increased patients' understanding of hard-to-resolve symptoms, Bianco says.
They also offer one another encouragement.
VanOrden, who has been active on Reddit, has this advice for other patients: "Don't give up. Continue to advocate for yourself. Somewhere out there is a doctor who will listen to you." She has started an alternative treatment — desiccated thyroid medication, an option not approved by the FDA — plus a low dose of the addiction drug naltrexone, though the data is limited. She's feeling better now.
Research of autoimmune thyroid disease gets little funding, so the underlying causes of immune dysfunction are not well studied, Henderson said. The medical establishment hasn't fully recognized hard-to-treat hypothyroid patients, but increased acknowledgment of them and their symptoms would help fund research, Bianco says.
"I would like a very clear, solid acknowledgment that these patients exist," he says. "These people are real."
KFF Health News, formerly known as Kaiser Health News (KHN), is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
veryGood! (67)
Related
- Apple iOS 18.2: What to know about top features, including Genmoji, AI updates
- Read the full text of the dissents in the Supreme Court's affirmative action ruling by Sotomayor and Jackson
- How a Farm Threatened by Climate Change Is Trying to Limit Its Role in Causing It
- Read the full text of the dissents in the Supreme Court's affirmative action ruling by Sotomayor and Jackson
- 2025 'Doomsday Clock': This is how close we are to self
- Court Sides With Trump on Keystone XL Permit, but Don’t Expect Fast Progress
- Harvard's admission process is notoriously tough. Here's how the affirmative action ruling may affect that.
- Aging Wind Farms Are Repowering with Longer Blades, More Efficient Turbines
- Brianna LaPaglia Reveals The Meaning Behind Her "Chickenfry" Nickname
- Overdose deaths from fentanyl combined with xylazine surge in some states, CDC reports
Ranking
- Alex Murdaugh’s murder appeal cites biased clerk and prejudicial evidence
- Read full text of the Supreme Court decision on web designer declining to make LGBTQ wedding websites
- Arnold Schwarzenegger Recalls Moment He Told Maria Shriver He Fathered a Child With Housekeeper
- Bling Empire's Anna Shay Dead at 62 After Stroke
- Paris Hilton, Nicole Richie return for an 'Encore,' reminisce about 'The Simple Life'
- I've Tried Over a Hundred Mascaras—This Is My New Go-To for the Quickest Faux-Looking Lashes
- New York City Aims for All-Electric Bus Fleet by 2040
- While It Could Have Been Worse, Solar Tariffs May Hit Trump Country Hard
Recommendation
Grammy nominee Teddy Swims on love, growth and embracing change
Court Sides With Trump on Keystone XL Permit, but Don’t Expect Fast Progress
Biden Signs Sweeping Orders to Tackle Climate Change and Rollback Trump’s Anti-Environment Legacy
Kathy Hilton Confirms Whether or Not She's Returning to The Real Housewives of Beverly Hills
Intel's stock did something it hasn't done since 2022
WHO questions safety of aspartame. Here's a list of popular foods, beverages with the sweetener.
To See Offshore Wind Energy’s Future, Look on Shore – in Massachusetts
You Might’ve Missed This Euphoria Star’s Cameo on The Idol Premiere